Endocrine Abstracts

A 26-year-old Caucasian male presented to the joint infertility outpatients clinic with primary infertility. His medical history included hypertrophic cardiomyopathy (HCM) due to genetically confirmed MYH7 sarcomere protein mutation, treated with implantable cardioverter-defibrillator while his partner was a healthy 24-year-old Caucasian nulliparous female. Initial investigations showed hypertestosteronemia (Testosterone: >51.0 nmol/l) and azoospermia, hence the c...

Aim: To explore the metabolic phenotype of Male Obesity-associated Secondary Hypogonadism (MOSH) and following treatment with long-acting intramuscular (IM) testosterone undecanoate.Methods: A prospective observational pilot study on metabolic effects of IM testosterone undecanoate in MOSH (Hypogonadal [HG] group, n=13), including baseline comparisons with controls (Eugonadal [EG] group, n=15). Half the subj...

Aim: To explore the metabolic phenotype of Male Obesity-associated Secondary Hypogonadism (MOSH) and following treatment with long-acting intramuscular (IM) testosterone undecanoate.Methods: A prospective observational pilot study on metabolic effects of IM testosterone undecanoate in MOSH (Hypogonadal [HG] group, n=13), including baseline comparisons with controls (Eugonadal [EG] group, n=15). Half the subj...

Background: Alemtuzumab is an anti-CD52 monoclonal antibody used in the treatment of relapsing and remitting Multiple Sclerosis (MS). It is a highly effective medication however common side effects of the treatment can include Autoimmune thyroid disease (Graves’ disease, Hashimoto’s thyroiditis), idiopathic thrombocytopenic purpura, anti-glomerular basement membrane disease, neutropenia, haemolytic anaemia, vitiligo being the most common presentation. This case highl...

Background: Secretory products from adipocytes may contribute to increased insulin resistance (IR). Retinol-binding protein-4 (RBP-4) may increase IR in mice, with elevated levels in insulin resistant mice and humans with obesity and type 2 diabetes. Mechanisms regulating RBP-4 synthesis remain not fully understood. It is not clear whether short-term hyperglycaemia alters RBP-4 levels in humans. In order to investigate this, we measured serum RBP-4 concentrations during 75 gra...

Polycystic ovary syndrome (PCOS) is associated with insulin resistance and obesity. Recent studies have shown that plasma omentin-1 levels decrease with obesity. Currently, no data exists on the relative expression and regulation of omentin-1 in adipose tissue (AT) of PCOS women.Objectives: To assess mRNA and protein levels of omentin-1 in omental (om) AT of PCOS women and matched controls, including circulating omentin-1. Ex vivo and in vivo</...

Context: Polycystic ovary syndrome (PCOS) is associated with insulin resistance (IR) and obesity, both predisposing factors to type 2 diabetes. A very recently described adipokine, retinol-binding protein 4 (RBP-4), has been shown to modulate insulin signalling and possibly lead to IR. At present, there is no data that depict the relative expression of RBP-4 in either serum or adipose tissue of PCOS women.Objectives: In women with PCOS compared to matche...

Aim: After almost 2 centuries, SGLT2-i have made their comeback in human pharmacology through successful re-introduction in diabetes type 2 (T2D). Via restriction of renal glucose reabsorption, SGLT2-i have shown promising results. The aim of this audit was to ensure that current practice at UHCW NHS Trust is in line with the agreed national standards, whilst collecting clinical data from the use of SGLT2-i.Methods: This...

A 26-year-old Caucasian male presented to the joint infertility outpatients clinic with primary infertility. His medical history included hypertrophic cardiomyopathy (HCM) due to genetically confirmed MYH7 sarcomere protein mutation, treated with implantable cardioverter-defibrillator while his partner was a healthy 24-year-old Caucasian nulliparous female. Initial investigations showed hypertestosteronemia (Testosterone: >...

Aim: After almost 2 centuries, SGLT2-i have made their comeback in human pharmacology through successful re-introduction in diabetes type 2 (T2D). Via restriction of renal glucose reabsorption, SGLT2-i have shown promising results. The aim of this audit was to ensure that current practice at UHCW NHS Trust is in line with the agreed national standards, whilst collecting clinical data from the use of SGLT2-i.Methods: This...